Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylos...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

Adalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...

Biocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...

Enzene or its parent Alkem which is commercialising the drug didn't announce the price, but said it would be competitively priced.

Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...

Glenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it t...

The product will be marketed by Hetero Healthcare under the brand name ‘MaburaTM’ in India, the company said.

For Infliximab, Reliance Life Sciences had completed process development, manufacturing, clinical trials in India and obtained marketing ap...

Key risks for Biocon going ahead include delay in launch of four key biosimilars in US or EU due to regulatory challenges, as well as highe...

The company had posted net profit of Rs 90.9 crore for the October-December period of the 2014-15 fiscal, Biocon said in a statement.

The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.

"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...

Biocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...

Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.